過大腎クリアランスを伴った感染症患者の予後：多施設後ろ向き研究 by 川野 恭雅
1 
 
Outcomes in patients with infections and augmented renal clearance: 
A multicenter retrospective study   
Short title: Outcomes in patients with infections and augmented renal 
clearance 
Yasumasa Kawano1*, Junichi Maruyama1, Ryo Hokama1, Megumi Koie1, Ryotaro 
Nagashima1, Kota Hoshino1, Kentaro Muranishi1, Maiko Nakashio1, Takeshi Nishida2, 
and Hiroyasu Ishikura1 
 
1Department of Emergency and Critical Care Medicine, Fukuoka University Hospital, 
Fukuoka, Japan 
2Department of Emergency and Critical Care Center, Kochi Health Sciences Center, 
Kochi, Japan 
 
*Corresponding Author: Yasumasa Kawano 
Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka 
University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 8140180, Japan  
Tel: +81-92-801-1011, Fax: +81-92-862-8330 
E mail: kawano0301@cis.fukuoka-u.ac.jp (YK)
2 
 
Abstract 1 
Recently, augmented renal clearance (ARC), which accelerates glomerular filtration of 2 
renally eliminated drugs thereby reducing the systemic exposure to these drugs, has 3 
started to receive attention. However, the clinical features associated with ARC are still 4 
not well understood, especially in the Japanese population. This study aimed to evaluate 5 
the clinical characteristics and outcomes of ARC patients with infections in Japanese 6 
intensive care unit (ICU) settings. We conducted a retrospective observational study 7 
from April 2013 to May 2017 at two tertiary level ICUs in Japan, which included 280 8 
patients with infections (median age 74 years; interquartile range, 64–83 years). We 9 
evaluated the estimated glomerular filtration rate (eGFR) at ICU admission using the 10 
Japanese equation, and ARC was defined as eGFR >130 mL/min/1.73 m2. Multivariable 11 
logistic regression analysis was performed to identify the independent risk factors for 12 
ARC and to determine if it was a predictor of ICU mortality. In addition, a receiver 13 
operating curve (ROC) analysis was performed, and the area under the ROC (AUROC) 14 
was determined to examine the significant variables that predict ARC. In total, 19 15 
patients (6.8 %) manifested ARC. Multivariable logistic regression analysis identified 16 
younger age as an independent risk factor for ARC (odds ratio [OR], 0.94; 95% 17 
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confidence interval [CI], 0.91–0.96). However, ARC was not found to be a predictor of 18 
ICU mortality (OR, 0.57; 95% CI, 0.11–2.92). In addition, the AUROC of age was 0.79 19 
(95% CI, 0.68–0.91), and the optimal cut off age for ARC was ≤63 years (sensitivity, 20 
68.4%; specificity, 78.9%). The incidence of ARC was, therefore, low among patients 21 
with infections in the Japanese ICUs. Although younger age was associated with the 22 
incidence of ARC, it was not an independent predictor of ICU mortality. 23 
 24 
 25 
Introduction 26 
Infections remain a leading cause of mortality among intensive care unit (ICU) patients 27 
despite numerous clinical advances [1]. For patients with infections, one of the most 28 
important approaches is to start treatment with adequate doses of appropriate antibiotics 29 
early on [2]. Recently, a phenomenon of augmented renal clearance (ARC), which 30 
influences the renal elimination of antibiotics, is gaining recognition [3, 4]. ARC occurs 31 
in a hyperdynamic state, caused by inflammatory mediators in critical conditions, and 32 
refers to an enhanced renal elimination of circulating solutes [5]. Since ARC accelerates 33 
glomerular filtration of renally eliminated drugs, it leads to a reduced systemic exposure 34 
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to these drugs [6-8]. Previous studies have shown the prevalence of ARC to be about 35 
14-80% in ICU patients [9-17]. Since creatinine clearance (CrCl) is not routinely 36 
measured in the ICUs for daily treatments [4], there is the challenge to detect ARC 37 
simply by the estimated glomerular filtration rate (eGFR), which is calculated using 38 
various formulas (such as the Cockcroft–Gault [CG] equation [18], Modification of Diet 39 
in Renal Disease [MDRD] Study equation [19], and the Chronic Kidney Disease 40 
Epidemiology Collaboration [CKD-EPI] equation [20]) in clinical practice worldwide. 41 
In addition, a Japanese eGFR equation is used to calculate eGFR [21] in the Japanese 42 
ICU settings. However, only a few studies on ARC that evaluated eGFR by using the 43 
Japanese equation have been reported. Furthermore, evidence for relevant clinical 44 
outcomes in Japanese ICU patients with ARC is still limited. The aims of this study 45 
were to determine the clinical characteristics and outcomes of patients with infections 46 
who also had ARC evaluated on the basis of eGFR calculated using the Japanese 47 
equation in ICU settings. 48 
 49 
 50 
Materials and methods 51 
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Setting 52 
This retrospective, two-multicenter, observational study was performed at two tertiary 53 
level ICUs in Japan, from April 2013 to May 2017. This study was approved by the 54 
Institutional Ethics Committees of the Fukuoka University Hospital and Kochi Health 55 
Sciences Center (numbers 17-10-03 and 171085). The opportunity was made for opting-56 
out, instead of giving informed consent individually. All data were fully anonymized for 57 
this study. 58 
Study Population 59 
The inclusion criteria for study admission were as follows: age ≥18 years, suspected 60 
infection and receiving antibiotics for therapeutic use. Patients were excluded if at the 61 
time of admission there was evidence of pregnancy, suspicion of rhabdomyolysis, 62 
serum creatine kinase (CK) concentration >5000 IU/L, renal impairment (serum 63 
creatinine [SCr] >1.1 mg/dL), or a history of renal replacement therapy.  64 
Data Collection and Definition 65 
The medical records collected at the time of admission were reviewed to investigate 66 
demographic and laboratory data, including age, sex, history of diabetic conditions, 67 
serum levels of albumin, CK, and creatinine, Acute Physiology and Chronic Health 68 
6 
 
Evaluation (APACHE) II scores, Sequential Organ Failure Assessment (SOFA) scores, 69 
ventilation variables, source of infection, the initial empirical choice of antibiotics 70 
including combined antibiotic therapy for infections, results of the blood culture, 71 
number of ICU-free days determined on day 28, and ICU mortality. 72 
ARC was defined as eGFR >130 mL/min/1.73 m2 [5]. An eGFR for diagnosing ARC in 73 
this study was calculated using a 3-variable Japanese equation [21]. 74 
For men: eGFR (mL/min/1.73 m2) = 194 × [SCr (mg/dL)]
−1.094 × age−0.287  75 
For women: eGFR (mL/min/1.73 m2) = 194 × [SCr (mg/dL)]
−1.094 × age−0.287 × 0.739  76 
Although, the eGFR calculated by CG, MDRD, and CKD-EPI was also evaluated in 77 
comparing the proportions of patients falling into various GFR ranges according to each 78 
equation. 79 
The SCr levels were determined by laboratory analysis using an enzymatic method.  80 
Statistical Analysis 81 
Results are expressed as mean (± standard deviation [SD]) or median (interquartile 82 
range [IQR]) for continuous data, and as a percentage for categorical data. The Student t 83 
test or Mann–Whitney U test and chi-square test were used for continuous and 84 
categorical data, respectively. Multivariable logistic regression analysis was performed 85 
to identify the independent risk factors for ARC and to determine if ARC can predict 86 
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ICU mortality. Because serum albumin levels and diabetic conditions have been shown 87 
to influence tubular creatinine secretion [22, 23], these factors were included as 88 
explanatory variables in a multivariate analysis for the risk factors of ARC. In addition, 89 
age and male sex, both of which are known risk factors for ARC, were also included as 90 
explanatory variables in this analysis [14, 15]. Furthermore, the explanatory variables in 91 
another multivariate analysis for the predictor of ICU mortality were determined from 92 
the ARC status and any variables with a p-value of less than 0.1 in the univariate 93 
analysis. The odds ratio (OR) and 95% confidence interval (CI) were calculated. 94 
Moreover, a receiver operating curve (ROC) analysis was performed, and the area under 95 
the ROC (AUROC), was determined to evaluate the accuracy of the significant 96 
variables in predicting ARC. All tests were two-tailed, and a p-value of <0.05 was 97 
considered statistically significant. 98 
All statistical analyses were performed by using the EZR software program (Saitama 99 
Medical Center, Jichi Medical University, Saitama, Japan) [24], which is a graphical user 100 
interface for the R software program (The R Foundation for Statistical Computing, Vienna, 101 
Austria). More precisely, it is a modified version of R commander, which was designed 102 
to add statistical functions frequently used in biostatistics. 103 
 104 
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 105 
Results 106 
Characteristics and clinical data  107 
Demographic, laboratory, treatment, and outcome data for the enrolled patients are 108 
shown in Table 1.  109 
 110 
Table 1. Baselines characteristics, laboratory, therapeutic, and outcome data 111 
Variables All patients (n = 280) ARC (n = 19) Non-ARC (n = 261) p value a 
Age (years), median (IQR) 74 (64-83) 46 (28-68) 75 (65-83) <0.05 
Sex, male, n (%) 145 (51.8) 9 (47.4) 136 (52.1) 0.81 
Mechanical ventilation, n (%) 113 (40.4) 12 (63.2) 101 (38.7) 0.05 
Diabetes mellitus, n (%) 47 (16.8) 4 (21.1) 43 (16.5) 0.54 
APACHE Ⅱ score, median (IQR) 20 (16-25) 23 (19-27) 20 (16-24) 0.06 
SOFA score, median (IQR) 5 (3-7) 6 (4-8) 5 (3-7) 0.17 
Serum albumin (g/dL), mean (SD) 2.9 (0.76) 2.8 (0.97) 2.9 (0.75) 0.52 
Serum CK (IU/L), median (IQR) 71.5 (35-155) 42 (25.5-76) 74 (35-159) 0.05 
Serum creatinine (mg/dL), median (IQR) 0.7 (0.6-0.9) 0.3 (0.3-0.37) 0.74 (0.6-0.9) <0.05 
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Positive blood culture, n (%) 71 (25.4) 3 (15.8) 68 (26.1) 0.42 
Site of infection, n (%) 
    
Lung 117 (41.8) 13 (68.4) 104 (39.8) <0.05 
Abdomen 80 (28.6) 3 (15.8) 77 (29.5) 0.29 
Skin and soft tissue 40 (14.3) 3 (15.8) 37 (14.2) 0.74 
Urinary tract 17 (6.1) - 17 (6.5) - 
Surgical site 7 (2.5) - 7 (2.7) - 
Heart 5 (1.8) - 5 (1.9) - 
Central nerve system 4 (1.4) - 4 (1.5) - 
Catheter 2 (0.7) - 2 (0.8) - 
Unknown 8 (2.9) - 8 (3.1) - 
Antibiotic, n (%) 
    
Carbapenems 137 (48.9) 6 (31.6) 131 (50.2) 0.15 
Piperacillin-tazobactam  63 (22.5) 6 (31.6) 57 (21.8) 0.39 
Ampicillin-sulbactam  45 (16.1) 6 (31.6) 39 (14.9) 0.1 
Linezolid 13 (4.6) 1 (5.3) 12 (4.6) 0.61 
Glycopeptides  13 (4.6) - 13 (5) - 
Clindamycin 9 (3.2) 2 (10.5) 7 (2.7) 0.12 
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Fluoroquinolones 7 (2.5) - 7 (2.7) - 
Cephalosporins 6 (2.1) 1 (5.3) 5 (1.9) 0.35 
Macrolides 6 (2.1) - 6 (2.3) - 
Daptomycin 3 (1.1) 1 (5.3) 2 (0.8) 0.19 
Others 8 (2.9) - 8 (3.1) - 
ICU-free days on Day 28, median (IQR) 21 (12-25) 19 (12-23) 22 (12-25) 0.23 
ICU mortality, n (%) 27 (9.6) 2 (10.5) 25 (9.6) 0.7 
ARC, augmented renal clearance; IQR, interquartile range; APACHE, Acute 112 
Physiology, and Chronic Health Evaluation; SOFA, Sequential Organ Failure 113 
Assessment; SD, standard deviation; CK, creatine kinase; ICU, intensive care unit. 114 
a The p values were evaluated by comparison between patients with and without ARC. 115 
 116 
We enrolled 280 patients in this study (median age, 74 years [IQR, 64–83 years], 51.8% 117 
men). The median APACHE II score was 20 (IQR, 16–25), and the median SOFA score 118 
was 5 (IQR, 3–7). Positive blood culture was reported for 71 (25.4%) of the patients. 119 
The most common site of infection was the lung (41.8%), and about half the patients 120 
received carbapenems (48.9%) for their treatment. While ICU mortality rate was 9.6%, 121 
ARC was seen in only 19 patients (6.8%). The age, SCr and incidence of lung infections 122 
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were significantly different between patients with and without ARC (all p <0.05), 123 
though the ICU mortality rates among the two groups were not significantly different (p 124 
=0.7). 125 
The patients with positive blood culture, with and without ARC were selected and 126 
compared for clinical data (Table 2). In about half the cases, the detected pathogen was 127 
gram-positive coccus (39/71, 54.9%). Including ICU mortality, there were no variables 128 
that showed a significant difference between patients with and without ARC. 129 
 130 
Table 2. Comparison of bacteriological and outcome data in patients with positive 131 
blood culture, with and without ARC  132 
Variables ARC (n=3) Non-ARC (n=68) p-value 
Microbiological examination, n (%) 
 
Gram positive coccus 2 (66.6) 37 (54.4) 1.0 
Gram-negative rods - 20 (29.4) - 
Gram-positive coccus and Fungus 1 (33.3) - - 
Fungus - 5 (7.4) - 
others - 6 (8.8) - 
ICU-free days on Day 28, median (IQR) 19 (9.5-21) 23 (13.8-25) 0.24 
12 
 
ICU mortality, n (%) 1 (33.3) 5 (7.4) 0.24 
ARC, augmented renal clearance; ICU, intensive care unit; IQR, interquartile range. 133 
 134 
The proportions of patients falling into various eGFR ranges as assessed by the 135 
Japanese, CG, MDRD, and CKD-EPI equations are shown in Table 3. The number of 136 
patients with an eGFR >130 mL/min/1.73 m2 was found to be different according to 137 
each equation; 19 patients (6.8%) were identified using the Japanese equation, 28 138 
patients (10%) using the CG equation, 57 patients (20.4%) with the MDRD equation, 139 
and 13 patients (4.6%) using the CKD-EPI equation. 140 
 141 
Table 3. Proportions of patients falling into various eGFR ranges as assessed by the 142 
Japanese, CG, MDRD, and CKD-EPI equations 143 
  
Japanese  
 n (%) 
CGa 
 n (%) 
MDRD 
 n (%) 
CKD-EPI  
n (%) 
eGFR >130 mL/min/1.73 m2  19 (6.8) 28 (10) 57 (20.4) 13 (4.6) 
130≥ eGFR >90 mL/min/1.73 m2  54 (19.3) 55 (19.6) 96 (34.3) 109 (38.9) 
90≥ eGFR >60 mL/min/1.73 m2  124 (44.3) 98 (35) 106 (37.9) 136 (48.6) 
60≥ eGFR >30 mL/min/1.73 m2  83 (29.6) 97 (34.6) 21 (7.5) 22 (7.9) 
30≥ eGFR >15 mL/min/1.73 m2  0 2 (0.7) 0 0 
eGFR ≤15 mL/min/1.73 m2  0 0 0 0 
eGFR, estimated glomerular filtration rate; CG, Cockcroft–Gault; MDRD, Modification 144 
of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology 145 
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Collaboration. 146 
a The CG equation was calculated with body surface area correction. 147 
 148 
Risk factors and predictive values for ARC 149 
Multivariable logistic regression analysis performed for four variables (age, male sex, 150 
history of diabetes mellitus, and serum albumin), indicated only younger age to be an 151 
independent risk factor for ARC (OR, 0.94; 95% CI, 0.91–0.96) (Table 4).  152 
 153 
Table 4. Multivariable logistic regression analysis for risk factors of ARC 154 
Variables OR (95% CI) p-value 
Age 0.94 (0.91-0.96) <0.05 
Male sex 0.82 (0.3-2.29) 0.71 
Diabetes mellitus 1.95 (0.55-6.9) 0.3 
Serum albumin 0.66 (0.35-1.26) 0.21 
ARC, augmented renal clearance; OR, odds ratio; CI, confidence interval. 155 
 156 
We performed the ROC analysis to evaluate age as a predictive factor for ARC. The 157 
AUROC of age was 0.79 (95% CI, 0.68–0.91), and the optimal cut off age for ARC was 158 
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≤63 years (sensitivity, 68.4%; specificity, 78.9%) (Table 5). 159 
 160 
Table 5. Age as a predictor of ARC using the receiver operating curves 161 
 
AUROC 95% CI 
Optimal 
cut off 
values 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Age (years) 
0.79 0.68-0.91 63 68.4 78.9 76.4 71.4 
ARC, augmented renal clearance; AUROC, area under the receiver operating curve; CI, 162 
confidence interval; PPV, positive predictive value; NPV, negative predictive value. 163 
 164 
Predictor of ICU mortality 165 
The comparison of clinical data between survivors and non-survivors are shown in 166 
Table 6. The following variables were significantly different between survivors and 167 
non-survivors: mechanical ventilation, APACHE II scores, SOFA scores and serum 168 
albumin (all p <0.05).  169 
 170 
Table 6. Comparison of clinical data between survivors and non-survivors 171 
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Variables Survivors (n = 253) Non-survivors (n = 27) p value 
ARC status, n (%) 17 (6.7) 2 (7.4) 0.7 
Age (years), median (IQR) 74 (64-83) 73 (65-79) 0.64 
Sex, male, n (%) 119 (53) 16 (40.7) 0.31 
Mechanical ventilation, n (%) 95 (37.5) 18 (66.7) <0.05 
Diabetes mellitus, n (%) 39 (15.4) 8 (29.6) 0.1 
APACHE II scores, median (IQR) 20 (16-24) 24 (17-28.5) <0.05 
SOFA scores, median (IQR) 5 (3-7) 7 (5-8) <0.05 
Serum albumin (g/dL), mean (SD) 2.9 (0.75) 2.6 (0.85) <0.05 
Serum CK (IU/L), median (IQR) 72 (35-155) 71 (42-141) 0.84 
Serum creatinine (mg/dL), median (IQR) 0.7 (0.6-0.9) 0.72 (0.5-0.9) 0.58 
Positive blood culture, n (%) 65 (25.7) 6 (22.2) 0.82 
Site of infection, n (%)    
Lung 101 (39.9) 16 (59.3) 0.06 
Abdomen 75 (29.6) 5 (18.5) 0.27 
Skin and soft tissue 37 (14.6) 3 (11.1) 0.78 
Urinary tract 17 (6.7) - - 
Surgical site 5 (2) 2 (7.4) 0.14 
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Heart 4 (1.6) 1 (3.7) 0.4 
Central nerve system 4 (1.6) - - 
Catheter 2 (0.8) - - 
Unknown 8 (3.2) - - 
Antibiotic, n (%)    
Carbapenems 124 (49) 13 (48.1) 1.0 
Piperacillin-tazobactam  55 (21.7) 8 (29.6) 0.34 
Ampicillin-sulbactam  43 (17) 2 (7.4) 0.27 
Linezolid 13 (5.1) - - 
Glycopeptides  11 (4.3) 2 (7.4) 0.36 
Clindamycin 7 (2.8) 2 (7.4) 0.21 
Fluoroquinolones 6 (2.4) 1 (3.7) 0.51 
Cephalosporins 5 (2) 1 (3.7) 0.46 
Macrolides 6 (2.4) - 1.0 
Daptomycin 3 (1.2) - 1.0 
Others 8 (3.2) - 1.0 
ARC, augmented renal clearance; IQR, interquartile range; APACHE, Acute 172 
Physiology, and Chronic Health Evaluation; SOFA, Sequential Organ Failure 173 
17 
 
Assessment; SD, standard deviation; CK, creatine kinase. 174 
 175 
Multivariable logistic regression analysis was performed for six variables including 176 
ARC status, mechanical ventilation, APACHE II scores, SOFA scores, serum albumin 177 
and lung infection. No variables, including ARC status (OR, 0.45; 95% CI, 0.08–2.46), 178 
were found to be an independent predictor of ICU mortality (Table 7).  179 
 180 
Table 7. Multivariable logistic regression analysis for a predictor of ICU mortality 181 
Variables OR (95% CI) p-value 
ARC status 0.45 (0.08-2.46) 0.36 
Mechanical ventilation 2.36 (0.97-5.75) 0.06 
APACHE Ⅱ scores 1.05 (0.99-1.12) 0.1 
SOFA scores 1.05 (0.9-1.23) 0.52 
Serum albumin 0.62 (0.34-1.1) 0.11 
Lung infection 1.85 (0.76-4.52) 0.18 
ICU, intensive care unit; OR, odds ratio; CI, confidence interval; ARC, augmented renal 182 
clearance; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, 183 
Sequential Organ Failure Assessment. 184 
18 
 
 185 
  186 
Discussion 187 
This study demonstrates a very low incidence of ARC in patients with infections and no 188 
renal impairment on the first hospital day. Our results show that younger age is an 189 
independent risk factor for ARC. In addition, the optimal cut off age for identifying 190 
ARC patients was ≤63 years. However, there was no significant difference in the ICU 191 
mortality rates between patients with and without ARC, even in those with a positive 192 
blood culture. Additionally, ARC status was not an independent predictor of ICU 193 
mortality.  194 
The percentage of patients with ARC in this study was 6.8%, which is much lower than 195 
the reported rates in previous studies [9-17]. There could be three reasons for this 196 
difference. First, different CrCl cutoff values have been used for diagnosing ARC in the 197 
previous studies. Because many previous studies have defined ARC as patients with a 198 
CrCl >130 mL/min/1.73 m2, we defined ARC as patients with an eGFR >130 199 
mL/min/1.73 m2 in this study [4]. However, while several previous reports have 200 
diagnosed ARC in cases with CrCl >130 mL/min/1.73 m2 [5, 9-11, 14-17], other studies 201 
have set the cutoff for CrCl at >120 mL/min/m2 [12, 13] and >160 mL/min/1.73 m2 [8]. 202 
19 
 
Though the best definition of ARC in the critically ill is still unknown, these different 203 
CrCl cutoff values could possibly account for the varying ARC prevalence rates 204 
reported by different studies including ours. Second, the different populations could 205 
account for the varying results among different studies. The risk factors for ARC have 206 
been reported to be young age, male sex, trauma and lower illness severity [14, 15]. The 207 
incidence of ARC reported, therefore, depends on how many subjects in a study have 208 
one or more of these risk factors. For instance, our study involved many elderly 209 
patients, with a median age of 74 years and the oldest patient was 106 years old. The 210 
relatively fewer number of young patients could, therefore, account for the lower 211 
prevalence of ARC seen in our study. Third, we assessed ARC retrospectively without a 212 
measurement for urinary CrCl. Instead, we used the eGFR values which were calculated 213 
by a Japanese equation for evaluating ARC. This Japanese equation has been reported to 214 
underestimate the GFR in ICU settings [10]. In addition, other commonly used formulas 215 
(such as CG, MDRD, and CKD-EPI) for eGFR worldwide have also been shown to 216 
underestimate the actual measured CrCl in ARC patients [16, 17]. As shown in our 217 
study, the different assessment techniques used, such as using various equations for 218 
diagnosing ARC, might have yielded different results for the incidence of ARC. 219 
A multivariate logistic regression analysis showed that younger age was an independent 220 
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risk factor for ARC, and a ROC analysis showed that the AUROC of age and cut off age 221 
were 0.79 and ≤63 years for screening ARC patients, respectively. Interestingly, these 222 
results are consistent with those of a previous study which evaluated ARC in patients by 223 
measuring CrCl for 8 h in Japanese ICU settings [10]. However, age cannot help 224 
identify the ARC patients accurately. Age should be used only as a screening tool for 225 
identifying ARC patients, and it is necessary to evaluate GFR for diagnosing ARC.  226 
We found that ARC was not associated with ICU mortality. Although many studies 227 
have shown that patients with infections and ARC have enhanced renal elimination of 228 
renally cleared antibiotics and therefore a reduced exposure to these drugs [6-8], there 229 
are still no studies showing the relationship between ARC and mortality [12, 25, 26]. 230 
The only adverse outcome, shown for patients with ARC in the previous studies, was 231 
the therapeutic failure of the antibiotics used [27-29]. If sepsis patients turn decline in 232 
status during their clinical course, a multi-organ failure including acute kidney injury 233 
(AKI) cannot be avoided [2]. Previous studies have demonstrated that AKI on 234 
admission was associated with both ICU and hospital mortality in sepsis patients [30]. 235 
However, ARC has been shown to occur in patients who had a lower illness severity 236 
without AKI [15]. Since these populations, who were at risk of ARC, also tended to 237 
have low mortality from the beginning, it might have been difficult to show the 238 
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correlation between ARC status on ICU admission and mortality. Nevertheless, 239 
therapeutic failure in patients with ARC might be an important outcome that physicians 240 
should pay attention to because it might be associated with the eventual acquisition of 241 
resistance to antimicrobial agents [28]. In addition, ARC might be associated with the 242 
prophylactic failure of antibiotic therapies given to trauma, burn, postoperative and 243 
immunocompromised patients.  244 
This study showed that no variables were independent predictors of ICU mortality. 245 
Interestingly, the severity of illness, evaluated by the SOFA and APACHE II scores, 246 
was not associated with ICU mortality. Although the reason for this lack of association 247 
is not clear, the underlying disease and comorbidities, which are not evaluated enough 248 
by these scoring systems, could have an effect on ICU mortality in a population that was 249 
not seriously ill and had a median SOFA score of 5 points in this study. 250 
This study has a number of limitations. First, this was a retrospective study, although it 251 
included two multicenters. Second, renal function was not evaluated by measuring the 252 
urinary or plasma clearance of an ideal filtration marker such as inulin [31]. Third, this 253 
study aimed to evaluate the ARC status on ICU admission only. Although the frequency 254 
of cases with ARC is high during the first day of ICU stay, it has been reported even 255 
during the first 7 days of ICU stay [12]. Fourth, there was no evaluation of whether the 256 
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empirical antimicrobial treatments, their doses and period used were appropriate for the 257 
patients with infections in this study. Finally, in this study, the SCr levels were evaluated 258 
by an enzymatic method, which was different from the Jaffe method used in a previous 259 
study. SCr levels measured by the Jaffe method have been shown to be higher than those 260 
by the enzymatic method [32]. Since the creatinine levels were used to diagnose ARC, 261 
the difference in the methods used for their estimation could have potentially impacted 262 
the findings of our study.  263 
 264 
 265 
Conclusion 266 
This study found that the incidence of ARC was low in Japanese ICU patients with 267 
infections and normal SCr levels on the day of admission. Younger age was found to be 268 
the only independent risk factor for ARC. Although age might be a useful screening tool 269 
for estimating ARC in patients, ARC itself was not a predictor of ICU mortality. Further 270 
studies are needed to determine the association between ARC and the adverse clinical 271 
outcomes, especially therapeutic failure/ prophylactic failure, in ICU settings.     272 
 273 
 274 
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